MEDPACE HOLDINGS Reports Earning Results for FY2023 Q2 on July 24, 2023.

🌥️Earnings Overview

On July 24, 2023, MEDPACE HOLDINGS ($NASDAQ:MEDP) reported their earnings results for the second quarter of FY2023. Total revenue for the period ending June 30, 2023 amounted to USD 460.9 million, an increase of 31.2% compared to the same quarter the prior year. Meanwhile, net income was a positive USD 61.1 million, rising 23.7% year over year.

Price History

On Monday, July 24th, 2023, MEDPACE HOLDINGS reported its earnings results for the second quarter of fiscal year 2023. Overall, the company’s results were slightly positive, as the company beat the market’s expectations. Investors responded positively to the news with the stock price rising 0.7%. MEDPACE HOLDINGS is expected to release more financial information in the coming weeks as investors await more details about the company’s performance. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Medpace Holdings. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Medpace Holdings. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Medpace Holdings. More…

Key Ratios Snapshot

Some of the financial key ratios for Medpace Holdings are shown below. More…

Analysis

At GoodWhale, we provide comprehensive analysis of the fundamentals of MEDPACE HOLDINGS. After a thorough examination of the company, our findings indicate that this is a high risk investment in terms of financial and business aspects. We have detected two risk warnings in its income sheet, which are non financial in nature. If you would like to take a closer look at these warnings, please register with us today. We hope you make informed decisions about investing in MEDPACE HOLDINGS. More…

Peers

Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.

– Icon PLC ($NASDAQ:ICLR)

Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.

– Syneos Health Inc ($NASDAQ:SYNH)

Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.

– IQVIA Holdings Inc ($NYSE:IQV)

IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.

Summary

Investors in MEDPACE HOLDINGS are likely to be pleased with the company’s performance for FY2023 Q2, as reported on July 24, 2023. Total revenue increased to USD 460.9 million, representing a 31.2% increase from the same period a year ago. Net income also increased 23.7% year over year to USD 61.1 million. This performance demonstrates MEDPACE HOLDINGS’ financial strength and resilience, making it an attractive investment opportunity for those interested in healthcare-related stocks.